Andere talen Takeda Pharmaceutical Company Limited Nyse

Aandelen

TAK

US8740602052

Beurs gesloten - Nyse Andere beurzen 22:00:02 25-06-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
12,98 ^USD	+0,78%		+2,45%	-9,04%

25/06	Amerikaanse CDC waarschuwt zorgverleners voor toename van denguegevallen	RE
25/06	Takeda's geneesmiddel tegen kanker krijgt goedkeuring van Europese Commissie	MT

Andere talen

Krijg toegang tot al het nieuws: wees als eerste op de hoogte en reageer voordat de beurs dat doet!

Gratis inschrijven

Takeda Announces New Assignments of Directors	09:06
US CDC alerts healthcare providers of increase in dengue cases	25/06
Takeda's Cancer Drug Gets European Commission Approval	25/06
Hutchmed China notes Takeda obtains EU approval for Fruzaqla	24/06
Takeda's Organ Transplant Infection Treatment Approved by Japan Regulators	24/06
Hutchmed (China), Takeda Secure EU Approval for Colorectal Cancer Treatment	24/06
Takeda Announces Approval of LIVTENCITY® (maribavir) in Japan for Post-Transplant Cytomegalovirus (CMV) Infection/Disease That Is Refractory to Existing Anti-CMV Therapies	24/06
Takeda Announces Approval of LIVTENCITY® by the Japanese Ministry of Health, Labour and Welfare	24/06
Japanese Shares End Higher as BoJ Indicates Readiness for Policy Shifts	24/06
Takeda Receives European Commission Approval for Colorectal Cancer Treatment	24/06
Takeda Receives European Commission Approval for FRUZAQLA® (fruquintinib)	24/06
Takeda Presents Late-Breaking Data from Phase 2b Study of Mezagitamab, Demonstrating Potential to Transform Treatment of Primary Immune Thrombocytopenia	23/06
Takeda Presents Late-Breaking Data from Phase 2b Study of Mezagitamab, Demonstrating Potential to Transform Treatment of Primary Immune Thrombocytopenia	23/06
Takeda Secures European Commission's Approval for Colorectal Cancer Drug Fruzaqla	21/06
Takeda Pharmaceutical Gets European Commission Approval for Cancer Treatment	21/06
Takeda Receives Approval from European Commission for FRUZAQLA in Previously Treated Metastatic Colorectal Cancer	21/06
Takeda Receives Approval from European Commission for Fruquintinib in Previously Treated Metastatic Colorectal Cancer	21/06
Takeda's HyQvia® Approved as Replacement Therapy for Primary Humoral Immunodeficiency and Secondary Humoral Immunodeficiency in Pediatric Patients 2 years of Age and Older	21/06
Les sorcières épouvantent l'IA	21/06
Japanese Stocks End Little Changed After Three-Day Winning Streak on Inflation and Yen Woes	21/06

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Takeda Pharmaceutical Company Limited Nyse

Aandelen

TAK

US8740602052

Andere talen

Filters